Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | RAF1 | P04049 | 9/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10266105 | 1.00 | RXFP1 (0.44) | RXFP1NPSR1KMT2AKDM4EHTT | |
| SCHEMBL10264603 | 0.88 | KDM4E (0.56) | KDM4EHTTATMRAF1MAPK14 | |
| SCHEMBL12949469 | 0.88 | KDM4E (0.56) | KDM4EHTTATMRAF1MAPK14 | |
| SCHEMBL12949749 | 0.81 | KMT2A (0.43) | RXFP1NPSR1KMT2AKDM4EHTT | |
| SCHEMBL10265008 | 0.80 | NR1I2 (0.50) | RXFP1NPSR1KMT2AKDM4EHTT | |
| SCHEMBL12812859 | 0.80 | NR1I2 (0.50) | RXFP1NPSR1KMT2AKDM4EHTT | |
| SCHEMBL12517149 | 0.80 | NPSR1 (0.43) | RXFP1NPSR1KMT2AKDM4EHTT | |
| SCHEMBL12949357 | 0.80 | NPSR1 (0.43) | RXFP1NPSR1KMT2AKDM4EHTT | |
| SCHEMBL12949474 | 0.80 | NPSR1 (0.43) | RXFP1NPSR1KMT2AKDM4EHTT | |
| SCHEMBL2875017 | 0.78 | KDM4E (0.72) | KMT2AKDM4EHTTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012006055-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | WO | disclosed |